Physician profile
Mohammad Jarbou
NPI 1396830915
$1,159.35
in general payments reported to CMS, 2019-2025
20 companies · $17.81 in 2025
The $17.81 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $183 · 2021: $119 · 2022: $137 · 2023: $126 · 2024: $122 · 2025: $17.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $162.02 | 2019-2024 | Fasenra, Tezspire, Breztri |
| Insmed, INC. | $161.04 | 2019-2023 | Arikayce |
| Glaxosmithkline, LLC. | $111.21 | 2019-2022 | |
| Grifols USA, LLC | $108.92 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $100.14 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.89 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $68.77 | 2022 | |
| Electromed, INC. | $52.42 | 2024 | Smartvest |
| Mylan Specialty L.P. | $39.50 | 2019-2020 | |
| Harmony Biosciences LLC | $38.80 | 2023-2025 | Wakix |
| Novartis Pharmaceuticals Corporation | $35.29 | 2019-2024 | |
| Vapotherm INC | $34.30 | 2019 | |
| Amgen INC. | $32.54 | 2024 | Tezspire |
| Inspire Medical Systems, INC. | $25.77 | 2023 | Inspire |
| Circassia INC. | $22.83 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $19.49 | 2019 | |
| Lilly USA, LLC | $16.70 | 2023 | Taltz |
| Pharming Healthcare, INC. | $16.30 | 2023 | Ruconest |
| Allergan, INC. | $14.29 | 2020 | |
| Resmed Corp | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Jarbou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.